Individuals with HIV/AIDS: Clinical Manifestations in the Oral Cavity in the Post-HAART Era

Ranjitha Krishna, Saiprasad Zemse and Scott Derossi
Georgia Health Sciences University, College of Dental Medicine
United States of America

1. Introduction

Oral lesions are very common in individuals with HIV (human immunodeficiency virus) infection and AIDS (acquired immune deficiency syndrome). They are reported to occur in 50% of people infected with HIV and in about 80% of people diagnosed with AIDS (Palmer, et al., 1996). Introduction of HAART (highly active anti-retroviral therapy) in 1996 has reduced the mortality and morbidity in people affected with HIV and AIDS as well as improved their quality of life. It has also resulted in a decrease, to a certain extent, in the incidence and prevalence of oral lesions.

Since HIV infection was first diagnosed in 1981, a variety of oral lesions has been associated with infected individuals, and they can be good indicators of the disease in otherwise healthy people. Oral lesions can also help determine the progression of the disease. In developed countries, CD4 lymphocyte counts and HIV viral load are the two main laboratory markers that are used to determine disease progression. However, in certain developing countries, people do not always have access to these tests, and severity of the oral lesions can serve as good indicators of disease progression.

Table 1 highlights the importance of diagnosing and treating oral lesions in individuals with HIV (Coogan, et al., 2005)

| 1. Can help diagnose the presence of HIV infection in otherwise healthy individuals |
| 2. Develop early in an infection |
| 3. Help determine the progression of HIV infection to AIDS |
| 4. Entry and end-points in vaccine trials |
| 5. Used in staging and classification of HIV diseases as determinants of opportunistic infection and anti-HIV therapy |

Table 1. Importance of oral manifestations of HIV disease

1.1 Classification of oral lesions associated with HIV

The EC-Clearinghouse on oral problems related to HIV infection and WHO Collaborating Centre on Oral manifestations of the immunodeficiency virus proposed the classification of oral manifestations of HIV infection in September of 1992 based on their strength of
association with the presence of HIV infection: ("Classification and Diagnostic Criteria for Oral Lesions in HIV Infection. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus," 1993). More recently in 2002, an international workshop was convened to discuss the classification of oral lesions associated with HIV/AIDS almost 2 decades after the virus was first identified (Patton, et al., 2002) and it was agreed that the original EC-Clearinghouse classification could still be used in current times. Table 2 summarizes the classification of oral lesions associated with HIV.

<table>
<thead>
<tr>
<th>Group 1: Lesions strongly associated with HIV infection</th>
<th>Group 2: Lesions less commonly associated with HIV infection</th>
<th>Group 3: Lesions seen in HIV infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Candidiasis</td>
<td>Bacterial infections:</td>
<td>Bacterial infections:</td>
</tr>
<tr>
<td>Hairy leukoplakia</td>
<td>Mycobacterium avium-intracellulare</td>
<td>Actinomyces israelii</td>
</tr>
<tr>
<td>Kaposi’s sarcoma</td>
<td>Mycobacterium tuberculosis</td>
<td>Escherichia coli</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>Melanogenic hyperpigmentation</td>
<td>Klebsiella pneumonia</td>
</tr>
<tr>
<td>Periodontal disease (linear gingival erythema,</td>
<td>Necrotizing (ulcerative) stomatitis</td>
<td>Cat-scratch disease</td>
</tr>
<tr>
<td>necrotizing ulcerative gingivitis, necrotizing</td>
<td>Salivary gland disease</td>
<td>Drug reactions (ulcerative, erythema</td>
</tr>
<tr>
<td>ulcerative periodontitis)</td>
<td>Dry mouth due to decreased salivary flow</td>
<td>multiforme, lichenoid, toxic</td>
</tr>
<tr>
<td></td>
<td>Unilateral/bilateral swelling of salivary glands</td>
<td>epidermolysis)</td>
</tr>
<tr>
<td></td>
<td>Thrombocytopenia purpura</td>
<td>Epithelioid (bacillary) angiomatosis</td>
</tr>
<tr>
<td></td>
<td>Non-specific ulcerations</td>
<td></td>
</tr>
<tr>
<td>Fungal infection other than candidiasis</td>
<td>Viral infections:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Herpes simplex virus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Human papillomavirus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Condyloma acuminatum</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Focal epithelial hyperplasia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Verruca vulgaris</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Varicella-zoster virus</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neurological disturbances:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Facial palsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trigeminal neuralgia</td>
</tr>
</tbody>
</table>

Table 2. Classification of oral lesions associated with HIV

In this chapter, we will discuss only those lesions that are commonly seen in persons infected with HIV.

2. Candidiasis

2.1 Background

Candidiasis is a common opportunistic infection caused by an overgrowth of the *Candida* microorganisms already present in the oral cavity. Incidence of oral candidiasis has been
high in developing countries (Tukutuku, et al., 1990). Since the discovery of HIV in 1981, candidiasis has been shown to be associated with HIV-infected individuals (Gottlieb, et al., 1981). Previous reports show that oral candidiasis occurs in 54-93% of individuals with AIDS (Schmidt-Westhausen, et al., 1991). In recent reports, due to the introduction of antiretroviral therapy only 20% of individuals infected with HIV showed oral candidiasis (Davies, et al., 2006).

2.2 Pathogenesis
Oral candidiasis is primarily caused by a dimorphic ubiquitous *Candida albicans*. The cell wall of *Candida* is primarily made up of three polysaccharides, mannan, glucan and chitin. *Candida* attaches to oral tissues and dentures with the help of adhesins such as Als1p, Als5p, Int1p and Hwp1p (Chaffin, et al., 1998, Hostetter, 1994). These glycoproteins bind to the extracellular matrix of mammalian cells such as fibrinogen, laminin and collagen (Chaffin, et al., 1998). Candidal adhesion to endothelial surfaces is achieved by the cell surface polysaccharide mannan, which binds to complement receptor 3 (CR3), an integrin found on human cells (Calderone and Braun, 1991). There is increased association of integrin analogs (iC3B and CR3d receptor) and fibronectin receptor with most of the virulent forms of *Candida* (Ollert, et al., 1990). Thus, CR3-like proteins promote adherence of *Candida albicans* to host cells.

2.3 Clinical features
There are three clinical forms of candidiasis: pseudo-membranous (thrush), erythematous (atrophic) and perioral angular chelitis. Proliferation of pseudo-membranous fungi forms a gray-white structure composed of inflammatory substrate and matted organisms resting on an erythematous base. These lesions are most commonly evident on the tongue, buccal mucosa, hard and soft palate and pharyngeal tissues. The erythematous form shows mucosal hyperemia and inflammation with a reddened erythematous patches (Calderone and Fonzi, 2001). The mucous membrane appears dry, red and glazed. Affected individuals show burning sensitivity and pain sensation of dry mouth, odynophagia, dysgeusia and smell of yeast infection. Angular chelitis shows commissural involvement as erythematous/hyperkeratotic with fissuring and sensitivity. Individuals receiving HAART show low occurrence of these clinical features. Before the emergence of HAART, the incidence of oral candidiasis was relatively high in persons with AIDS.

2.4 Treatment
An early study for treatment of *Candida* infections was carried out by Williams in 1977, where nystatin was compared to no treatment in 56 patients (Williams, et al., 1977). Since then ketoconazole, fluconazole, clotrimazole, itraconazole, neomycin sulphate, colistin, trimethoprin and sulphamethoxazole have been tried in combination and at different concentrations for treatment of oral candidiasis (Hann, et al., 1982, Owens, et al., 1984, Palmblad, et al., 1992, Philpott-Howard, et al., 1993, Rozenberg-Arska, et al., 1991, Vogler, et al., 1987). Most recently ketoconazole and clotrimazole were found most effective in treatment of oral candidiasis (Worthington, et al., 2002). Initial local treatments are first line of therapy (Bensadoun, et al., 2008). Mucosal contact for 2 minutes is recommended either by rinsing, gargling or swallowing.
Systemic treatments are considered in high-risk patients only when local therapy fails (Charlier, et al., 2006). When topical and systemic therapy fails, intravenously administered amphotericin B and echinocandins are considered in high-risk patients. Intermittent use of antifungal agents has been advocated to prevent development of resistant fungal infections (Samaranayake, et al., 2002). Recently, gel formulation of fluconazole has proven to be a better alternative treatment form than tablet formulation (Nairy, et al.).

Fig. 1. Cell wall of Candida albicans

Fig. 2. Hypertrophic Candidiasis
Fig. 3. Pseudo-membranous Candidiasis

Fig. 4. Atrophic/Erythematous Candidiasis
3. Hairy leukoplakia

3.1 Background
OHL (Oral hairy leukoplakia) is caused by Epstein-Barr virus and was first described in 1984. 50% of individuals with HIV present with this condition and it is a very good indicator of immunosuppression. The lesion usually presents itself when the CD4 cell counts fall below $0.3 \times 10^9/L$ (Bravo, et al., 2006). According to the CDC (Centers for Disease Control and Prevention), this condition has a clear prognostic value in predicting the future development of AIDS ("1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS among Adolescents and Adults," 1992).

3.2 Pathogenesis
The pathogenesis of OHL is due to the replication of Epstein-Barr virus and increased virulence in conjunction with a decrease in local and systemic host immunity.

3.3 Clinical features
OHL present themselves as white, corrugated lesions on the lateral surface of the tongue and are not painful. There has been a decrease in the incidence of OHL due to the potent
Individuals with HIV/AIDS: Clinical Manifestations in the Oral Cavity in the Post-HAART Era

3.4 Treatment

OHL is a relatively benign condition with low morbidity and does not require any specific treatment. Most of the time, these lesions resolve spontaneously. However, several treatment options are available for those who feel uncomfortable or have cosmetic concerns due to the lesion. Since the lesion is caused by multiplication of the Epstein-Barr virus, topical and systemic anti-viral agents work effectively in resolving the lesion. High doses of Acyclovir (800 mg 5 times a day) (Resnick, et al., 1988), Valacyclovir (1000 mg 3 times a day), and Famciclovir (500 mg 3 times a day) have all been shown to resolve the lesions in 1-2 weeks (Schofer, et al., 1987). However, once the effect of the anti-viral agent wears off, the lesions can recur several weeks later.

Topical application of Podophyllin resin in 25% solution has produced resolution of the lesion in 1-2 weeks (Gowdey, et al., 1995). Topical therapy with retinoic acid has also been shown to cause resolve the lesions due to inhibition of Epstein-Barr virus replication. Ablative and cryotherapy have also had success in treatment of the lesions. Although the above treatment options are effective in resolving the lesion, OHL can recur several weeks after treatment since none of these agents eliminate the latent state of infection.
4. Kaposi’s sarcoma

4.1 Background
KS (Kaposi’s sarcoma) is an angioproliferative tumor described by the Hungarian pathologist Moritz Kaposi in 1872. It is caused by KSHV (Kaposi’s sarcoma-associated herpes virus) or γ2-herpes virus. KSHV belongs to the genus Rhadinovirus and has a DNA sequence similar to other rhadinoviruses (Albrecht, et al., 1992). With the introduction of HAART in 1996, the incidence of AIDS-related cancers such as KS and NHL (non-Hodgkin’s lymphoma) has decreased (Shiels, et al., 2008). During the 1980s and early 1990s, US population rates of KS increased 30 fold (Eltom, et al., 2002). There were no KS cases during 1975-1979, before the advent of AIDS. In an HIV cancer match study, 81% of KS cases matched to HIV registries during 1980-2007 (Shiels, et al., 2011). AIDS occurred in a higher proportion of patients with Kaposi’s sarcoma in age groups of 0-29 and 30-59 years (Shiels, et al., 2011).

4.2 Pathogenesis
KS lesions show varying cell diversity. Lesions are flat, comprising of inflammatory cells (T, B cells and monocytes). Neovascularization develops prior to development of these lesions and contain spindle-shaped cells. This dermal stage progresses to the plaque stage, in which the lesions are more indurated, edematous, and red or violet in color. The lesion eventually reaches the nodular stage and is characterized by visible masses with dominant spindle cells and inflammatory cells. These spindle cells express lymphatic-specific markers (e.g., Podoplanin and lymphatic vessel hyaluronan receptor LYVE-1) as well as participate in the signaling process during lymphangiogenesis (Skobe, et al., 1999, Weninger, et al., 1999).

4.3 Clinical features
There are four types of KS: classic type, endemic African KS, KS in organ transplant recipients, and HIV-infection/AIDS associated KS (Trattner, et al., 1993). KS is the most common neoplasm (20-50%) found in HIV-infected individuals (mostly homosexual and bisexual men) (Scully, et al., 1991). Oral lesions are evident in 40% of KS (Greenspan and Greenspan, 1990). Red or purplish macules, papules or nodules appear most frequently on the hard palate (Greenspan and Greenspan, 1990). Unless infected or ulcerated, these lesions do not blanch on pressure (Greenspan and Greenspan, 1990). Laryngeal involvement is also evident in individuals with KS (Pantanowitz and Dezube, 2006). Primary symptoms are hoarseness, throat discomfort, urge to cough, aphonia, dysphagia, stridor, and complete airway obstruction.

4.4 Treatment
The extent and bulk of the disease determines the therapeutic alternative that needs to be considered. Individuals with fewer than five cutaneous lesions are kept on watch until rapid proliferation, widespread dissemination or KS-related symptoms become more apparent. Treatment with HAART or other anti-retroviral therapies are beneficial and have shown histologic regression of existing lesions (Eng and Cockerell, 2004). HAART therapy causes inhibition of HIV replication, diminishes the HIV-1 transactivating protein Tat, ameliorates the immune response against KSHV, and shows direct anti-angiogenic activity (Cattelan, et al., 1999, Pati, et al., 2002, Sgadari, et al., 2002). Radiotherapy is
indicated for lesions on the face, hands and upper extremities, obstructive lymphadenopathy, periorbital edema, lesions on soles of the feet, anorectal or genital lesions, oral lesions and ulcerating cutaneous lesions. Radiotherapy shows merits in symptomatic disease where systemic treatment is not necessary and expensive chemotherapy can be avoided (Swift, 1996). If an active opportunistic infection is observed, chemotherapeutic agents should be considered. Systemic chemotherapeutic treatment is indicated in extensive KS of oral cavity, widespread skin involvement, pedal or scrotal edema, symptomatic visceral involvement and flare induced by immune reconstitution inflammatory syndrome (Osoba, et al., 2001). Individuals may suffer from neutropenia and thrombocytopenia and hence controlled therapy should be the choice of treatment. Only nodular and symptomatic lesions of oropharynx should be treated with radiation. Recombinant and non-recombinant alpha interferons can be used for treatment of epidemic KS (De Wit, et al., 1988).

Fig. 7. Kaposi’s Sarcoma

5. Human Papilloma Virus (HPV) infections

5.1 Background

HPV is the leading cause of oropharyngeal carcinomas (D’Souza, et al., Rosenquist, 2005). HPV16 is a common cause for the majority of oropharyngeal carcinomas (Kreimer, et al., 2005) . HPV-positive individuals are most frequently Caucasian and belong to high socioeconomic status (Gillison, et al., 2008). HIV-infected individuals have two to four-fold increase in risk for developing HPV-related oral cancers (Gilbert, et al.). HPV has also been considered as one of the etiologic factors for OHL (oral hairy leukoplakia) (Fejerskov, et al., 1977), as shown by identification of HPV antigens and HPV DNA (Loning, et al., 1985). HPV-induced OL shows prevalence ranged from 17% to 68.6% (Shroyer, et al., 1993, Sugiyama, et al., 2003).
5.2 Pathogenesis
HPV is mainly infectious through expression of oncogenes such as E6/E7 (Al-Bakkal, et al., 1999), which cause phosphorylation of CHK2, leading to caspase activation (Al-Bakkal, et al., 1999, Moody and Laimins, 2009, Tominaga, et al., 1999). The intrinsic apoptotic pathway of caspase activation plays an important role in HPV replication (Moody, et al., 2007). HPV proteins flourish and regulate amplification primarily by caspase activation, leading to immortalization of the suprabasal layer of epithelium, specifically the keratinocytes (Sakai, et al., 1996).

5.3 Clinical features
HPV induced oral and pharyngeal cancers are most evident in younger females (<40 years). OSCC (oral squamous cell carcinoma) normally occur on the buccal mucosa (2-10%), lip (4-40%), alveolar ridge (2-18%) retromolar trigonous (2-6%), hard palate (3-6%), floor of mouth (25%), ventral two third of tongue (50%), alveolar ridge (2-18%), floor of mouth (25%) and oropharynx (25%). Squamous cell carcinoma of the oropharynx most commonly originates in the tonsils and tongue base (the two most common sites), pharyngeal walls, and soft palate.

Fig. 8. Human Papilloma Virus Lesions
5.4 Treatment
Treatment of HPV infection can be achieved either by use of targeted therapy against the virus or immune-stimulating therapy. Most dysplastic tissue can be treated by ablative and excisional therapy. Use of radiochemotherapy in the form of radiation ± cisplatin or cetuximab has shown beneficial results in treatment of oropharyngeal carcinoma. The overall survival rate was 60% in HPV-positive individuals and 73% in HPV-negative individuals (Lill, et al.).

6. Periodontal lesions associated with HIV
6.1 Linear Gingival Erythema (LGE)
6.1.1 Background
This lesion is also known as ‘red-band gingivitis’ or ‘HIV-associated gingivitis’. LGE is commonly seen in immune-compromised individuals and is considered to be a potential precursor for necrotizing ulcerative gingivitis (NUG)/necrotizing ulcerative periodontitis (NUP). According to the recent classification of periodontal diseases (Armitage, 1999), LGE is classified under ‘Gingival diseases of fungal origin.’

6.1.2 Pathogenesis
There is an increased number of bacteria and Candida species in the gingival sulcus associated with LGE. The bacteria seen include those commonly observed in periodontal disease such as Bacteriodes gingivalis, Bacteriodes intermedius, Actinomyces viscosus, Fusobacterium nucleatum, and Aggregatibacter actinomycetemcomitans.

6.1.3 Clinical features
The lesions present themselves as 2-3 mm wide red band around the marginal gingival of the teeth. These lesions are not typically painful, but bleed readily.

6.1.4 Treatment
Typically, no treatment is needed for this condition. Although LGE is listed under ‘Lesions of fungal origin’, it is not typically treated with anti-fungal medications. Mechanical removal of plaque and calculus helps reduce inflammation and excessive bleeding. Chlorhexidine gluconate (0.12%) mouth rinses can be used twice daily. If the lesion persists, systemic antibiotics (metronidazole) may be prescribed to reduce the bacterial load.

6.2 Necrotizing Ulcerative Gingivitis and Periodontitis (NUG and NUP)
6.2.1 Background
NUG is a painful condition of the gingiva characterized by ulcerations, bleeding, and foul breath. It is also called Vincent’s infection, Vincent’s angina, or trench mouth. When the infection spreads to the alveolar bone, it is called NUP. Prevalence of NUP in HIV-infected individuals has been reported by various researchers. Its prevalence with HIV was reported in 1994 as 6% (Glick, et al., 1994). Over a period of a decade, the incidence of HIV in NUP patients increased to 69.6% (Shangase, et al., 2004). Recent reports suggest 43% of patients with NUP were HIV-seropositive (Phiri, et al.). Studies have shown that HIV-infected individuals with NUP are 20.8% more likely to have a CD4+ count lower than 200 (Glick, et al., 1994).
6.2.2 Pathogenesis

NUP is commonly a progression of NUG that demonstrates bone loss and clinical attachment levels (MacCarthy and Claffey, 1991). Both are primarily caused by bacterial infection with microflora consisting of Treponema and Selenomonas species, *Prevotella intermedia*, *Fusobacterium nucleatum* and *Porphyromonas gingivalis* (Falkler, et al., 1987, Loesche, et al., 1982). Malnutrition, smoking, stress, trauma and preexisting gingivitis are other etiologic factors (Peruzzo, et al., 2007, Taiwo, 1993). Most persons with NUG have alterations in the immune system making them more prone to microbial infections (Cogen, et al., 1983). This immunosuppression is also evident in infection by HIV (Goedert, et al., 1984). *Treponema denticola* (*T. denticola*) is the principal oral helical-shaped anaerobic spirochete that plays an essential role in immunosuppression. The disease process is mediated through adherence to mucosal surfaces, specific cleavage of cell surface receptors, inhibition of host defense mechanisms, penetration in epithelial cells, and induction of gingival inflammation and bone resorption. Proteases such as chymotrypsin, phospholipase C, oligopeptidase and cystalysin play an important role in pathogenicity (Chi, et al., 2003, Ellen and Galimanas, 2005, Fenno and McBride, 1998) and is induced by a range of pro-inflammatory cytokines such as IL-1α, IL-1β, tumor necrosis factor-α, IL-6 and IL-8 (Gemmell and Seymour, 1998, Nixon, et al., 2000). These cytokines affect connective tissue destruction and alveolar bone resorption (Gemmell and Seymour, 1998). Phosphorylation of intracellular receptors such as Fos-c, MKK1, MAP kinase and nuclear factor κB molecules by *T. denticola* affect these changes (Tanabe, et al., 2008).
6.2.3 Clinical features
The clinical characteristics of NUG includes ulcerated and necrotic papillary and marginal gingival covered by a yellowish-white or grayish slough or “pseudomembrane”, blunting and cratering of papillae, spontaneous bleeding or bleeding on probing, pain and fetid breath (Barnes, et al., 1973, Falkler, et al., 1987, Horning and Cohen, 1995). It may be accompanied by fever, lymphadenopathy, and malaise. Progression of gingivitis to NUP is commonly associated with clinical attachment loss and alveolar bone destruction.

![Fig. 10. Necrotizing Ulcerative Periodontitis](image)

6.2.4 Treatment
The first treatment for NUG was devised by Dr. S. Schluger in 1949 (Schluger, 1949). Bacterial pathogens were controlled or eliminated by mechanical debridement or use of antibiotics in earlier days (Johnson and Engel, 1986). Aureomycin and penicillin were the first antibiotics considered for treatment of NUG in 1950 (Goldman and Bloom, 1950, Montis, 1950). Mechanical treatment consists of scaling and root planing. In addition to mechanical debridement, antibiotic and antimicrobial therapies are essential for management of NUP. Oxidizing mouthwash such as 3% hydrogen peroxide has also shown to have beneficial effects in management of NUG and NUP.

7. Non-Hodgkin lymphoma
7.1 Background
There are three subtypes of non-Hodgkin’s lymphoma (NHL): diffuse large B cell lymphoma (DLBCL), Burkitt’s lymphoma (BL) and central nervous system lymphoma (CNSL)(Engels,
et al., 2006). An increase in occurrence of DLBCL (10.2%), BL (27.8%) and CNSL (48.3%) was seen in individuals with AIDS during 1990-1995 (Shiels, et al., 2011). The 5-year survival rate improved from 1960 to the mid 1970s, but not much after that in the USA (Shiels, et al., 2011). NHL relates to congenital and acquired immunodeficiency diseases (Filipovich, et al., 1992). The relative risk of NHL in individuals with AIDS is about 150-250 in Western countries and over 1000 in children (Goedert, 2000).

7.2 Pathogenesis

The head and neck regions are the most common sites for NHL, showing in 30-40% of cases (Economopoulos, et al., 1996). The neoplastic cells express CD20, CD79, BCL-2 and BCL-6, most of which are B-cell antigens (Hoefnagel, et al., 2003). The hallmark of B-cell malignancies is chromosomal translocation involving the immunoglobulin heavy chain (IGH) gene at band 14q32.33 with specific oncogene loci, referred to as the 14q32 translocation. Among these specific 14q32 translocations, de novo acute leukemia/lymphoma with c-MYC and/or BCL6 abnormalities in addition to t(14;18) was characterized by an extremely aggressive clinical course with nodal and/or extranodal involvement, and massive bone marrow infiltration(Kramer, et al., 1991). Incidence of IGH translocation on B-cell NHL has been reported in previous studies (Kramer, et al., 1998). Thus multiple involvement of the IGH gene in chromosomal rearrangements is associated with the pathogenesis and the progression of NHL.

Fig. 11. Histology of NUP lesion- Infiltration of Spirochetes into the Connective Tissue
Stage I
- Involvement of a single lymph node region (I) or a single extralymphatic organ or site (IE)

Stage II
- Involvement of two or more lymph node regions on the same side of the diaphragm (II) alone or with localized involvement of an extralymphatic organ or site (IIIE)

Stage III
- Involvement of lymph node regions on both sides of the diaphragm (III) alone or with localized involvement of an extralymphatic organ or site (IIIES) or spleen (IIIS) or both (IIISE)

Stage IV
- Diffuse or disseminated involvement of one or more extralymphatic organs with or without associated lymph node involvement

Table 3. Ann Arbor Classification of Non-Hodgkin’s Lymphomas (Rupniewska, 1979)

7.3 Clinical features
Oral NHL lesions are often in disseminated disease states. The most common oral sites of involvement are the palate, tonsil, buccal mucosa, floor of the mouth, and the retromolar region. These lesions are non-tender, diffuse swellings usually involving the gingiva, buccal vestibule and posterior hard palate. Gnathic lesions arise from soft tissue invading the bony skeleton. One third of patients show fever, weight loss, adenopathy, night sweats, or hepatosplenomegaly. Oral lesions are fluctuant swellings showing ulceration, pain, tooth mobility and paresthesia when peripheral nerves are involved (Vega, et al., 2005). Salivary gland lymphomas account for approximately 3% of all salivary gland tumors (Barnes, et al., 1998). About 80% of the cases are reported in parotid gland, 16% in submandibular, 2% in sublingual and 2% in minor salivary glands. Affected bony areas show a "punched out" pattern that is due to multiple areas of destruction with ill defined radiolucent lesion. Involvement of the maxillary sinus will cause opacification with eroded cortical walls and associated sinus mass (Fukuda, et al., 1987). The Ann Arbor staging system, originally designed for Hodgkin’s disease, is used for NHL as evident above.

7.4 Treatment
A prognostic index has been developed by the International NHL prognostic factors project based on data from 2,031 patients with aggressive lymphomas treated with regimens containing doxorubicin ("A Predictive Model for Aggressive Non-Hodgkin's Lymphoma," 1993). Analysis of 1274 patients younger than 60 years showed three clinical features independently associated with survival: serum LDL (lactate dehydrogenase) levels, tumor stage, and their performance status ("A Predictive Model for Aggressive Non-Hodgkin's Lymphoma," 1993). Past studies showed the importance of gallium-67 uptake in lymphomas as a useful prognostic indicator (Janicek, et al., 1997). The importance of prognostic index is that good-risk patients can be identified for standard therapy and poor-risk patients can be identified for new research protocols to improve the rate of therapy. With conventional therapy only 25% of patients who were gallium-positive midway through therapy had durable responses, while 70% of those who were gallium-negative remained free of disease (Janicek, et al., 1997). In patients with stage I or II disease, regional therapy leads to long-term control, with relapse rate of 44%-47% at 10 years and survival rates of 75% for patients younger than 60 years (Vaughan Hudson, et al., 1994). Stage III and IV patients can be treated by alkylating agents, combination chemotherapy regimens with 2-4 drugs, and high
dose therapy with bone marrow transplant reinfusion (Freedman, et al., 1996, Govindan, et al., 2009).

8. Conclusions

Thorough examination of the oral cavity should be part of the physical examination for everybody, but especially in HIV-positive individuals and those who are at a high risk for acquiring HIV infection. Oral lesions can not only compromise the quality of life and increase morbidity in patients with HIV/AIDS, but can also serve as indicators for the presence of the disease and disease progression. It is also very important for health care providers and medical practitioners from different specialties to collaborate in providing the overall care for these immune-compromised patients.

9. References


Individuals with HIV/AIDS: Clinical Manifestations in the Oral Cavity in the Post-HAART Era


Individuals with HIV/AIDS: Clinical Manifestations in the Oral Cavity in the Post-HAART Era


Osoba, David, Donald W. Northfelt, David W. Budd, and David Himmelberger. "Effect of Treatment on Health-Related Quality of Life in Acquired Immunodeficiency Syndrome (Aids)-Related Kaposi's Sarcoma: A Randomized Trial of Pegylated-
Individuals with HIV/AIDS: Clinical Manifestations in the Oral Cavity in the Post-HAART Era


Global View of HIV Infection
Edited by Dr. Vishwanath Venketaraman

Hard cover, 176 pages
Publisher InTech
Published online 26, October, 2011
Published in print edition October, 2011

Some of the topics covered in this book are: HIV infection HIV transmission Clinical symptoms of AIDS AIDS and opportunistic infection Prevention and treatment of HIV Treatment of HIV infection and immune reconstitution

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:


InTech Europe
University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821